The $680m deal includes UCB’s brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and its Zhuhai manufacturing site, and was made in partnership with Mubadala Investment Co.
CBC Group buys UCB's China mature neurology and allergy arm
Leave a comment
Your Trusted Source for Accurate and Timely Updates!
Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Using RSS feeds, we aggregate news from trusted sources to ensure real-time updates on the latest events and trends. Stay ahead with timely, curated information designed to keep you informed and engaged.
